Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.60 |
| ▸ | GLP1R | P43220 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | YAP1 | P46937 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24329285 | 0.90 | PRMT5 (0.53) | PRMT5GLP1RGPR119 | |
| SCHEMBL24329538 | 0.88 | PRMT5 (0.49) | PRMT5GLP1RGAATHRBSMN1; SMN2 | |
| SCHEMBL25952601 | 0.87 | HPGD (0.49) | PRMT5GAATHRBSMN1; SMN2GPR119 | |
| SCHEMBL10196271 | 0.86 | PRMT5 (0.52) | PRMT5GAATHRBSMN1; SMN2GPR119 | |
| SCHEMBL24329756 | 0.86 | PRMT5 (0.49) | PRMT5GLP1RGAASMN1; SMN2GPR119 | |
| SCHEMBL29555212 | 0.86 | PRMT5 (0.49) | PRMT5GLP1RGAASMN1; SMN2GPR119 | |
| SCHEMBL25338674 | 0.85 | PRMT5 (0.48) | PRMT5GLP1RGAAGPR119 | |
| SCHEMBL29241227 | 0.84 | MET (0.49) | PRMT5GLP1RGPR119 | |
| SCHEMBL29491290 | 0.84 | MET (0.49) | PRMT5GLP1RGPR119 | |
| SCHEMBL27083269 | 0.84 | PRMT5 (0.46) | PRMT5GLP1RGAATHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PRMT5 4322/4885GLP1R 1/4885GAA 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.